Skip to content
Menu
search button
mobile search close icon
Close

Welcome to the ADCES Media Center

Find the latest information from reputable sources for your news stories about diabetes care and education.

Media Relations

ADCES Media Center

The Association of Diabetes Care & Education Specialists is home to experts on various topics related to diabetes care and education. We welcome the opportunity to provide you with sources and resources about what we do and the impact we have on people with diabetes and the healthcare system. 

 

Media Contact

For more information, contact Danielle McNary in ADCES® Media Relations at 312-601-4805 or [email protected].

Talking About Diabetes

Language & Diabetes in the Media

How we talk about diabetes in the media has an impact. Using descriptive and non-judgmental language when talking about diabetes or about people with diabetes can make a positive difference. If you’re a member of the media, please take a moment to review these suggestions when covering stories on diabetes.

View Our Language Guide

Quotes From Diabetes Spokespeople

Get expert commentary, story ideas and background information on the full range of prediabetes, diabetes and cardiometabolic related topics from ADCES volunteer diabetes spokespeople. If you’re writing an article on any of these subjects, consider interviewing one of our qualified diabetes care and education experts.

Meet Our Spokespeople

ADCES & Diabetes in the Media

Learn more about ADCES’s contributions, activities and events surrounding the education, management and prevention of prediabetes, diabetes and related cardiometabolic conditions in our latest news releases.

ADCES names Katelyn O’Brien 2026 Diabetes Care and Education Specialist of the Year

Aug 10, 2025, 16:32 by Diana Pihos
ADCES is pleased to announce that Katelyn O’Brien, PharmD, BCPS, CDCES, BC-ADM, a clinical pharmacy specialist in adult endocrinology at Boston Medical Center, has been selected as the recipient of the 2026 Diabetes Care and Education Specialist of the Year Award. This award is sponsored by Xeris Pharmaceuticals, Inc.

PHOENIX, AZ CHICAGO, IL August 9, 2025—The Association of Diabetes Care & Education Specialists (ADCES) is pleased to announce that Katelyn O’Brien, PharmD, BCPS, CDCES, BC-ADM has been selected as the recipient of the 2026 Diabetes Care and Education Specialist of the Year Award.  This award is sponsored by Xeris Pharmaceuticals, Inc.

O’Brien is a clinical pharmacy specialist in adult endocrinology at Boston Medical Center, the largest safety net hospital in New England. Since earning her Certified Diabetes Care and Education Specialist (CDCES) credential in 2017, O’Brien has focused on increasing access to diabetes technologies and promoting the use of evidence-based therapies, including SGLT2 inhibitors and incretin-based treatments, for high-need populations.

O’Brien has been an active contributor to professional education and advocacy within the diabetes care community. She has presented at both state and national Association of Diabetes Care & Education Specialists (ADCES) conferences, served as co-chair of the ADCES Pharmacy Community of Interest, and currently holds the role of Chair of the Massachusetts Coordinating Body. In this leadership capacity, she has helped expand local volunteer involvement and engagement initiatives.

The Diabetes Care and Education Specialist of the Year Award honors a diabetes care and education specialist who has made a special contribution to the field through dedication, innovation and sensitivity in care. O’Brien has played a pivotal role in implementing continuous glucose monitoring (CGM) systems in primary care clinical settings. Her work includes designing workflows, securing reimbursement pathways, training clinicians, and integrating CGM data into electronic health records. Additionally, she co-developed endocrine telementoring sessions that support collaborative discussion of complex cases and promote person-centered care across healthcare teams.

Just this year, she received Boston University’s "Continuing Education Outstanding Champion Award," recognizing her significant contributions to provider education and collaborative care models.

“I am truly honored to receive this recognition from ADCES and what it represents - the shared commitment of so many working to improve diabetes care and empower patients on a daily basis. It is a privilege to support individuals living with diabetes and reduce barriers to evidence-based treatments, technologies, and screenings,” said O’Brien. “I wish to extend my gratitude to those that nominated me, the ADCES Awards Committee, and Xeris Pharmaceuticals for their continued support for this award. Thank you!”

About The Association of Diabetes Care & Education Specialists

ADCES is an interdisciplinary professional membership organization dedicated to improving prediabetes, diabetes and cardiometabolic care through innovative education, management and support. With more than 11,000 professional members including nurses, dietitians, pharmacists and others, ADCES has a vast network of practitioners working to optimize care and reduce complications. ADCES supports an integrated care model that lowers the cost of care, improves experiences and helps its members lead so better outcomes follow. Learn more at adces.org or visit us on Facebook or LinkedIn (Association of Diabetes Care & Education Specialists), X (@ADCESdiabetes) and Instagram (@ADCESdiabetes).  

About Xeris Pharmaceuticals, Inc.

Xeris Pharmaceuticals, Inc. is a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, and a gastrointestinal motility inhibitor when used during radiology exams as a diagnostic aid; and Keveyis®, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous injection for hypothyroidism, as well as several early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for its partners.

Xeris Pharmaceuticals is a wholly owned subsidiary of Xeris Biopharma Holdings, (Nasdaq: XERS) which is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow them on XLinkedIn, or Instagram.

Leave a comment Newest on top Oldest on top
Load more comments
avatar
Login to be able to comment